Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Intestinal Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Digestive System Neoplasm
Intestinal Neoplasm

Cancer Family

Intestinal Neoplasm

CI-CAN-00000209Explore in graph →

Non-malignant1,893 active trials21 approved drugs383 evidence items

NCIt: C3141
MeSH: D007414

Overview
Statistics
Survival
Genomics28
Variants & evidence383
Drugs80
Trials9158
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (371)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 201–225 of 371 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours.
· Eur J Cancer · 2016 · PMID 26812186 · validated civic_curation pubmed
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.
· J Clin Oncol · 2015 · PMID 26460303 · validated civic_curation pubmed
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
· Lancet · 2012 · PMID 22608338 · validated civic_curation pubmed
Cetuximab for the treatment of colorectal cancer.
· N Engl J Med · 2007 · PMID 18003960 · validated civic_curation pubmed
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
· Cancer Discov · 2011 · PMID 22586653 · validated civic_curation pubmed
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
· Lancet Oncol · 2016 · PMID 27108243 · validated civic_curation pubmed
A common variant in MTHFR influences response to chemoradiotherapy and recurrence of rectal cancer.
· Am J Cancer Res · 2015 · PMID 26693073

Showing 201–225 of 371 publications

← Previous
1
…
8
9
10
…
15
Next →

· validated civic_curation

Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.

· Cancer Discov · 2016 · PMID 27729313 · validated civic_curation pubmed

GNAS1 T393C polymorphism and survival in patients with sporadic colorectal cancer.

· Clin Cancer Res · 2005 · PMID 16033819 · validated civic_curation pubmed

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

· Lancet Oncol · 2010 · PMID 20619739 · validated civic_curation pubmed

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.Retracted

· N Engl J Med · 2015 · PMID 26287849 · validated civic_curation pubmed

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.

· J Clin Oncol · 2018 · PMID 29320312 · validated civic_curation pubmed

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer.

· Cancer Discov · 2017 · PMID 28363909 · validated civic_curation pubmed

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.

· Cancer Discov · 2018 · PMID 29431699 · validated civic_curation pubmed

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

· J Clin Oncol · 2010 · PMID 20008640 · validated civic_curation pubmed

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.

· J Clin Oncol · 2011 · PMID 21502544 · validated civic_curation pubmed

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

· Lancet · 2011 · PMID 21641636 · validated civic_curation pubmed

BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis.

· Colorectal Dis · 2013 · PMID 24112392 · validated civic_curation pubmed

Plasma versus tissue tumor mutational burden as biomarkers of durvalumab plus tremelimumab response in patients with metastatic colorectal cancer in the CO.26 trial.

· Clin Cancer Res · 2024 · PMID 38727700 · validated civic_curation pubmed

The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer.

· Nat Commun · 2023 · PMID 37666855 · validated civic_curation pubmed

Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer.

· N Engl J Med · 2025 · PMID 40961426 · validated civic_curation pubmed

The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.

· Acta Oncol · 2014 · PMID 24666267 · validated civic_curation pubmed

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.

· Lancet Oncol · 2015 · PMID 26184520 · validated civic_curation pubmed

Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.

· Clin Cancer Res · 2013 · PMID 23325582 · validated civic_curation pubmed

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

· Cancer Res · 2006 · PMID 16618717 · validated civic_curation pubmed